RedHill Biopharma (RDHL) Cash from Operations (2016 - 2022)
Historic Cash from Operations for RedHill Biopharma (RDHL) over the last 11 years, with Q4 2022 value amounting to -$2.4 million.
- RedHill Biopharma's Cash from Operations rose 8370.68% to -$2.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$29.2 million, marking a year-over-year increase of 5513.38%. This contributed to the annual value of -$9.4 million for FY2024, which is 7384.42% up from last year.
- Per RedHill Biopharma's latest filing, its Cash from Operations stood at -$2.4 million for Q4 2022, which was up 8370.68% from -$6.0 million recorded in Q3 2022.
- In the past 5 years, RedHill Biopharma's Cash from Operations ranged from a high of -$2.4 million in Q4 2022 and a low of -$19.0 million during Q3 2021
- Over the past 5 years, RedHill Biopharma's median Cash from Operations value was -$10.0 million (recorded in 2018), while the average stood at -$10.8 million.
- Per our database at Business Quant, RedHill Biopharma's Cash from Operations crashed by 10744.74% in 2021 and then skyrocketed by 8370.68% in 2022.
- Over the past 5 years, RedHill Biopharma's Cash from Operations (Quarter) stood at -$8.2 million in 2018, then plummeted by 69.26% to -$13.9 million in 2019, then grew by 8.39% to -$12.7 million in 2020, then decreased by 16.95% to -$14.9 million in 2021, then surged by 83.71% to -$2.4 million in 2022.
- Its last three reported values are -$2.4 million in Q4 2022, -$6.0 million for Q3 2022, and -$16.6 million during Q2 2022.